OMass Therapeutics
Oxford University spinout developing small-molecule medicines.
OMass Therapeutics announced $310m on 15 October 2026 to advance its hormone-disorder drug OMS1620 through Phase 2 development, with Bain Capital Life Sciences, Forbion and Novo Holdings leading the round.
Last refreshed: 22 October 2026
Timeline for OMass Therapeutics
Closed a $310m Series C
UK Startups and Innovation: Oxford's OMass raises $310m on foreign leadsUK startups raise $6.1bn in Q3, below Dealroom's pace
UK Startups and InnovationBackground
OMass Therapeutics is an Oxford biotechnology company developing small-molecule medicines for endocrine and immune diseases. It grew out of Carol Robinson’s laboratory at the University of Oxford, applying native mass spectrometry research to drug discovery. That scientific origin underpins its focus on difficult biological targets. [Company profile](https://www.globenewswire.com/news-release/2026/10/15/3381281/0/en/OMass-therapeutics-announces-310-million-series-c-financing-to-advance-portfolio-of-small-molecule-therapeutics-in-endocrinology-and-immunology.html)
Its OdyssION platform combines native mass spectrometry, biochemistry and custom chemistry. The approach examines a target together with its surrounding molecular interactions, while separating it from the full complexity of a cell. This lets OMass study how potential medicines interact with that target in a controlled setting. The platform is the company’s drug-discovery method; it supplies candidates for subsequent clinical development and testing. [OMass](https://www.OMass.com/)
OMass funds its next clinical programme
On 15 October 2026, OMass announced a $310m Series C to advance its lead medicine, OMS1620, through Phase 2 development. For the Oxford spinout, the financing backs work on congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, the two hormone disorders targeted by the programme.
The October round brought Bain Capital Life Sciences, Forbion and Novo Holdings into the lead investor group, alongside participation from existing shareholders. OMass also allocated proceeds to its earlier pipeline, including initial clinical data for an immune-disease programme. Those were development plans, with clinical results still to be established.
What will OMass's Series C fund?
Who led OMass's $310m financing?
What diseases is OMS1620 being developed for?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 22 October 2026. Editorial standards.